<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337698</url>
  </required_header>
  <id_info>
    <org_study_id>BO39610</org_study_id>
    <secondary_id>2017-001267-21</secondary_id>
    <nct_id>NCT03337698</nct_id>
  </id_info>
  <brief_title>A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)</brief_title>
  <acronym>Morpheus Lung</acronym>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based
      treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC).

      Two cohorts will be enrolled in parallel in this study: the first-line cohort will consist of
      patients who have not received any systemic therapy for their disease and the second-line
      cohort will consist of patients who progressed after receiving a platinum-containing
      chemotherapy regimen and a checkpoint-inhibitor treatment. In each cohort, eligible patients
      will be assigned to one of several treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Anticipated">April 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Objective response</measure>
    <time_frame>Every 6 weeks (starting on Day 1, Cycle 1) for the first 48 weeks and then every 6 or 12 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival After Randomization</measure>
    <time_frame>Randomization to death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Alive at Month 6 and at Month 12</measure>
    <time_frame>Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>First occurrence of a documented objective response to disease progression or death (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline through the end of the study (approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of Atezolizumab</measure>
    <time_frame>Day 1, Cycle 1 prior to study treatment and 30 minutes after IV; Day 1 of cycles 2,3,4,8,12 and 16, prior to study treatment; Treatment discontinuation; 120 days after last dose of Atezolizumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of Cobimetinib</measure>
    <time_frame>Day 15, Cycle 1 prior to treatment and 2-4 hours after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of RO6958688</measure>
    <time_frame>Day 1, Cycles 1-17 and subsequent, prior to treatment and at end of RO6958688 infusion; at treatment discontinuation; 30 days after last dose of atezolizumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of Docetaxel</measure>
    <time_frame>Day 1, Cycle 1 5 minutes before end of infusion and 1 hour after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of BL-8040</measure>
    <time_frame>Priming period Day 1 before treatment, 1 hour after dose and Day 5 1 hour after dose; Day 15, Cycle 1, and Day 1, Cycles 2, 3, 4, 8, 12, 16 before treatment, 1 hour after dose; Day 1, Cycle 20 and every 4 cycles thereafter before treatment; treatment end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of Tazemetostat</measure>
    <time_frame>Day 1, Cycle 2 prior to treatment and 1,2 and 4 hours after dose; Day 1, Cycles 3 and 4 prior to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Serum Concentration of CPI-444</measure>
    <time_frame>Day 1, Cycles 2 and 4 prior to treatment and 2-5 hours after dose</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezo arm will receive treatment until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezo + Cobi arm will receive treatment until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
Participants who progressed on 3L treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab+ RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezo + RO6958688 arm will receive treatment until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
Participants who progressed on 3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the Docetaxel arm will receive treatment until unacceptable toxicity or disease progression.
Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 treatment, provided they meet the eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + BL-8040</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezo + BL-8040 arm will receive treatment until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + Tazemetostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Tazemetostat arm will receive treatment until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + CPI-444</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezo + CPI-444 arm will receive treatment until unacceptable toxicity or loss of clinical benefit.
Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment until unacceptable toxicity or loss of clinical benefit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment until unacceptable toxicity or loss of clinical benefit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Atezolizumab + Docetaxel arm will receive treatment until unacceptable toxicity or loss of clinical benefit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Day 1 and 15 of each 28 day cycle.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Atezolizumab+ RO6958688</arm_group_label>
    <arm_group_label>Atezolizumab + BL-8040</arm_group_label>
    <arm_group_label>Atezolizumab + Tazemetostat</arm_group_label>
    <arm_group_label>Atezolizumab + CPI-444</arm_group_label>
    <arm_group_label>Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_label>Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_label>Atezolizumab + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib is administered orally on days 1-21 of a 28 day cycle.</description>
    <arm_group_label>Atezolizumab + Cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6958688</intervention_name>
    <description>Cycle 1:
RO6958688 is administered by IV infusion on days 1, 8 , and 15 of a 21 day cycle at increasing dosage.
Subsequent cycles:
RO6958688 is administered by IV infusion on days 1, 8 , and 15 of a 21 day cycle</description>
    <arm_group_label>Atezolizumab+ RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is administered by IV on day 1 of each 21 day cycle.</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_label>Atezolizumab + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL-8040</intervention_name>
    <description>BL-8040 is administered by subcutaneous injection on Days 1-5 during the 5-day priming period prior to Cycle 1; BL-8040 is administered by subcutaneous injection three times a week (days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle)</description>
    <arm_group_label>Atezolizumab + BL-8040</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat is administered orally twice daily on days 1-21 out of a 21 day cycle.</description>
    <arm_group_label>Atezolizumab + Tazemetostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444</intervention_name>
    <description>CPI-444 is administered orally twice daily on Days 1- 21, out of a 21 day cycle.</description>
    <arm_group_label>Atezolizumab + CPI-444</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed is administered by IV on Day 1 of a 21 day cycle.</description>
    <arm_group_label>Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.</description>
    <arm_group_label>Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_label>Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle</description>
    <arm_group_label>Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1

          -  Life expectancy greater than or equal to 3 months

          -  Histologically or cytologically confirmed metastatic, non-squamous or squamous
             Non-Small Cell Lung Cancer (NSCLC)

          -  Measurable disease (at least one target lesion)

          -  Adequate hematologic and end-organ function

          -  Tumor accessible for biopsy

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive measures as outlined for each specific
             treatment arm

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm, as outlined for
             each specific treatment arm

        Exclusion Criteria

          -  Prior allogeneic stem cell or solid organ transplantation

          -  Current treatment with anti-viral therapy for hepatitis B virus (HBV)

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently)

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases

          -  History of leptomeningeal disease

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
             active pneumonitis on screening chest computed tomography scan

          -  History of malignancy other than NSCLC within 2 years prior to screening

          -  Active tuberculosis

          -  Severe infection within 4 weeks prior to initiation of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO39610 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Mac Callum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)</name>
      <address>
        <city>Songpa-gu</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31620</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Cancer Institute</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

